{"podcast":{"title":"The Bio Report","slug":"the-bio-report-1092382","podcast_index_feed_id":1092382,"rss_url":"https://feed.podbean.com/thebioreport/feed.xml","website_url":"https://thebioreport.podbean.com","image_url":"https://pbcdn1.podbean.com/imglogo/image-logo/15149796/BRlogo_znb5nt.jpg","author":"Levine Media Group","episode_count":615,"summary":"The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.","last_synced_at":null,"page_url":"https://stenobird.com/podcast/the-bio-report-1092382"},"episode":{"title":"A Strategic Turn from Obesity to Cancer","slug":"a-strategic-turn-from-obesity-to-cancer","published_at":"2026-02-18T08:00:00+00:00","page_url":"https://stenobird.com/podcast/the-bio-report-1092382/a-strategic-turn-from-obesity-to-cancer","show_page_url":"https://stenobird.com/podcast/the-bio-report-1092382","url":"https://thebioreport.podbean.com/e/a-strategic-turn-from-obesity-to-cancer/","audio_url":"https://mcdn.podbean.com/mf/web/26b77zys8m8dq3ih/BR-Amy_Burroughs-2-19-267rayx.mp3","summary":"When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals, she not only had to fill a void created by the death of her predecessor, but also lead a strategic shift from an increasingly crowded area of metabolic disease to focus on its experimental therapy for chronic myeloid leukemia. The company’s allosteric BCR-ABL inhibitor binds to a different site on the fusion protein than most first- and second-generation tyrosine kinase inhibitors. The data have the company and its investors believing the drug can reset the bar for both efficacy and tolerability in a multibillion-dollar market. We spoke with Burroughs about reinventing the company, the decision to seek partners for non-core assets, and how she is charting a clear path toward a broader oncology future.","meta_description":"When Amy Burroughs stepped in as CEO of Terns Pharmaceuticals, she not only had to fill a void created by the death of her predecessor, but also lead a st…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1373,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/a-strategic-turn-from-obesity-to-cancer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-bio-report-1092382/a-strategic-turn-from-obesity-to-cancer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}